|
|
Phase II Study of Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Relapsed Hematologic Malignancies After Prior High-Dose Chemotherapy and Autologous Stem Cell Transplantation
Alternate Title Basic Trial Information Objectives Entry Criteria Expected Enrollment Outcomes Outline Published Results Trial Contact Information Registry Information
Alternate Title
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer
Basic Trial Information
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II
|
|
|
|
Treatment
|
|
|
|
Closed
|
|
|
|
Under 70
|
|
|
|
NCI
|
|
|
|
CALGB-100002 NCT00053196
|
|
|
Objectives - Determine the feasibility of non-myeloablative allogeneic hematopoietic stem cell transplantation by demonstrating that the risk of treatment-related mortality during the first 6 months is an acceptable rate of less than 40% in patients with relapsed hematologic malignancies after prior high-dose chemotherapy and autologous stem cell transplantation.
- Determine the response rates (disease-specific partial and complete response) in patients treated with this regimen.
- Determine the 6-month and 12-month probabilities of response in patients treated with this regimen.
- Determine the distribution of time-to-progression in patients responding to this regimen.
- Determine the percent donor chimerism in patients treated with this regimen.
- Determine the risk of acute and chronic graft-vs-host disease in patients treated with this regimen.
- Determine the toxic effects of this regimen in these patients.
- Determine the disease-free and overall survival of patients treated with this regimen.
Entry Criteria Disease Characteristics:
- Histologically confirmed hematologic malignancy, including one of the following:
- Chronic lymphocytic leukemia (CLL)
- Absolute lymphocytosis greater than 5,000/mm3
- Lymphocytes must appear morphologically mature with less than 55% prolymphocytes
- Lymphocyte phenotype with expression of CD19 and CD5
- Prolymphocytic leukemia (PLL)
- Morphologically confirmed
- Absolute lymphocytosis greater than 5,000/mm3
- More than 55% prolymphocytes
- Non-Hodgkin's lymphoma or Hodgkin's lymphoma
- Any WHO histologic subtype allowed except mantle cell lymphoma
- Core biopsies allowed if they contain adequate tissue for primary diagnosis and immunophenotyping
- No bone marrow biopsy as the sole diagnostic means for follicular lymphoma
- Multiple myeloma
- Active disease requiring treatment
- Durie-Salmon stage I, II, or III
- Acute myeloid leukemia
- Documented control (i.e., less than 10% bone marrow blasts and no circulating blasts)
- Myelodysplastic syndromes
- Documented disease by WHO criteria
- Must have evidence of relapse/progression at least 6 months after prior high-dose chemotherapy with autologous hematopoietic stem cell support
- Absence of CD23 expression for CLL or PLL allowed provided there is no morphologic evidence of mantle cell lymphoma
- Availability of any of the following donor types:
- HLA-identical sibling (6/6)
- 9/10 matched related donor by high-resolution molecular typing at HLA A, B, C, DRB1, and DQB1 loci
- Only a single mismatch at one class I or II allele allowed
- 10/10 matched unrelated donor by high-resolution molecular typing at HLA A, B, C, DRB1, and DQB1 loci
- No syngeneic donors
Prior/Concurrent Therapy:
Biologic therapy - See Disease Characteristics
Chemotherapy - See Disease Characteristics
- More than 4 weeks since prior chemotherapy
Endocrine therapy Radiotherapy - More than 4 weeks since prior radiotherapy
Surgery - More than 4 weeks since prior surgery
Patient Characteristics:
Age Performance status Life expectancy Hematopoietic - See Disease Characteristics
Hepatic - Bilirubin no greater than 3 times upper limit of normal (ULN)
- AST no greater than 3 times ULN
Renal - Creatinine clearance at least 40 mL/min
Cardiovascular - LVEF at least 30% by MUGA
Pulmonary - DLCO greater than 40%
- No symptomatic pulmonary disease
Other - Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- HIV negative
- No uncontrolled diabetes mellitus
- No active serious infection
- No known hypersensitivity to E. coli-derived products
Expected Enrollment A total of 20-80 patients will be accrued for this study within 10-40 months. Outcomes Primary Outcome(s)Treatment-related mortality
Secondary Outcome(s)Complete response Complete or mixed donor chimerism Disease-free survival Graft-versus-host disease
Outline This is an open-label study. Patients are followed within 2-3 months, every 3 months for 2 years, and then every 6 months for 3 years. Published ResultsBashey A, Owzar K, Johnson JL, et al.: Reduced-intensity allogeneic transplantation after failure of autologous transplantation: a prospective multi-center CALGB study. [Abstract] Blood 108 (11): A-3122, 2006.
Trial Contact Information
Trial Lead Organizations Cancer and Leukemia Group B | | | Asad Bashey, MD, PhD, Protocol chair(Contact information may not be current) | | | |
Registry Information | | Official Title | | Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation For Patients With Disease Relapse Or Myelodysplasia After Prior Autologous Transplantation | | Trial Start Date | | 2002-12-15 | | Registered in ClinicalTrials.gov | | NCT00053196 | | Date Submitted to PDQ | | 2002-11-15 | | Information Last Verified | | 2006-04-08 | | NCI Grant/Contract Number | | CA31946 |
Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol. Back to Top |
|